Our previous data demonstrated that the frequency of BP1 positivity, and the distribution and intensity of BP1 expression, increased with the progression of tumor development (normal→ hyperplasia→in situ→ invasive), from a few randomly distributed BP1 positive cell clusters in normal controls to the vast majority of cells in the invasive tumors showing distinct BP1 immunoreactivity [9]. Here, DLX4 is linked to neoplasm.